垂体神经内分泌肿瘤病例报道1例并文献复习
Pituitary Neuroendocrine Tumor: A Case Report and Review of Literature
DOI: 10.12677/acm.2024.14112989, PDF,   
作者: 龙浩健*, 周镇锋*, 黎 山*, 杨 兰*：暨南大学第一临床医学院，广东 广州；赵建夫#, 陈文慧#：暨南大学附属第一医院(广州华侨医院)肿瘤科，广东 广州
关键词: 泌乳素巨腺瘤；垂体；垂体神经内分泌瘤；磁共振成像；Prolactin Giant Adenoma； Hypophysis； PitNET； Magnetic Resonance Imaging
摘要: 垂体催乳素腺瘤(prolactin-secreting adenoma, PRLoma)是最常见的功能性垂体腺瘤，约占成人垂体功能性腺瘤的40%，泌乳素微腺瘤较为常见，很少发展为大腺瘤，最大直径大于40 mm的泌乳素巨腺瘤并不常见。本文报道1例43岁男性患者，检查颅脑CT初次发现鼻咽部肿物时显示鼻咽区占位54 mm × 55 mm，已达到泌乳素巨腺瘤标准。本文针对催乳素瘤的诊断、鉴别及治疗策略进行文献回顾。
Abstract: Prolactin-secreting adenoma (PRLoma) is the most prevalent functional pituitary adenoma, accounting for approximately 40% of adult functional pituitary adenomas. Prolactin microadenomas are relatively common and rarely progress into large adenomas. Prolactin giant adenomas with a maximum diameter exceeding 40 mm are infrequent occurrences. In this paper, we present a case study of a 43-year-old male patient diagnosed with a nasopharyngeal mass measuring 54 mm × 55 mm through craniocranial CT scan, which fulfills the criteria for prolactin giant adenoma. This article provides an overview of the literature concerning the diagnosis, differentiation, and treatment of prolactinoma.
文章引用：龙浩健, 周镇锋, 黎山, 杨兰, 赵建夫, 陈文慧. 垂体神经内分泌肿瘤病例报道1例并文献复习[J]. 临床医学进展, 2024, 14(11): 1103-1110. https://doi.org/10.12677/acm.2024.14112989

参考文献

[1] Colao, A. (2009) The Prolactinoma. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 575-596. [Google Scholar] [CrossRef] [PubMed]
[2] Moraes, A.B., Marques dos Santos Silva, C., Vieira Neto, L. and Gadelha, M.R. (2013) Giant Prolactinomas: The Therapeutic Approach. Clinical Endocrinology, 79, 447-456. [Google Scholar] [CrossRef] [PubMed]
[3] Maiter, D. and Delgrange, E. (2014) Therapy of Endocrine Disease: The Challenges in Managing Giant Prolactinomas. European Journal of Endocrinology, 170, R213-R227. [Google Scholar] [CrossRef] [PubMed]
[4] Fernandez, A., Karavitaki, N. and Wass, J.A.H. (2010) Prevalence of Pituitary Adenomas: A Community-Based, Cross-Sectional Study in Banbury (Oxfordshire, UK). Clinical Endocrinology, 72, 377-382. [Google Scholar] [CrossRef] [PubMed]
[5] Shimon, I., Sosa, E., Mendoza, V., Greenman, Y., Tirosh, A., Espinosa, E., et al. (2016) Giant Prolactinomas Larger than 60 Mm in Size: A Cohort of Massive and Aggressive Prolactin-Secreting Pituitary Adenomas. Pituitary, 19, 429-436. [Google Scholar] [CrossRef] [PubMed]
[6] Shimon, I. (2021) Prolactinomas: Diagnosis and Medical Treatment. In: Pituitary Tumors, Elsevier, 175-185. [Google Scholar] [CrossRef] 
[7] Guaraldi, F., Ambrosi, F., Ricci, C., Di Sciascio, L. and Asioli, S. (2024) Histopathology of Growth Hormone-Secreting Pituitary Tumors: State of the Art and New Perspectives. Best Practice & Research Clinical Endocrinology & Metabolism, 38, Article 101894. [Google Scholar] [CrossRef] [PubMed]
[8] Tsukamoto, T. and Miki, Y. (2023) Imaging of Pituitary Tumors: An Update with the 5th WHO Classifications—Part 1. Pituitary Neuroendocrine Tumor (Pitnet)/Pituitary Adenoma. Japanese Journal of Radiology, 41, 789-806. [Google Scholar] [CrossRef] [PubMed]
[9] Fujino, K., Yasufuku, K., Kudoh, S., Motooka, Y., Sato, Y., Wakimoto, J., et al. (2017) INSM1 Is the Best Marker for the Diagnosis of Neuroendocrine Tumors: Comparison with CGA, SYP and CD56. International Journal of Clinical and Experimental Pathology, 10, 5393-5405.
[10] Asa, S.L., Mete, O., Perry, A. and Osamura, R.Y. (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 33, 6-26. [Google Scholar] [CrossRef] [PubMed]
[11] Asa, S.L., Casar-Borota, O., Chanson, P., Delgrange, E., Earls, P., Ezzat, S., et al. (2017) From Pituitary Adenoma to Pituitary Neuroendocrine Tumor (Pitnet): An International Pituitary Pathology Club Proposal. Endocrine-Related Cancer, 24, C5-C8. [Google Scholar] [CrossRef] [PubMed]
[12] Rindi, G., Klimstra, D.S., Abedi-Ardekani, B., Asa, S.L., Bosman, F.T., Brambilla, E., et al. (2018) A Common Classification Framework for Neuroendocrine Neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) Expert Consensus Proposal. Modern Pathology, 31, 1770-1786. [Google Scholar] [CrossRef] [PubMed]
[13] Lee, C.H. (2023) Pituitary Neuroendocrine Tumor: Is It Benign or Malignant? Brain Tumor Research and Treatment, 11, 173-176. [Google Scholar] [CrossRef] [PubMed]
[14] Villa, C., Baussart, B., Assié, G., Raverot, G. and Roncaroli, F. (2023) The World Health Organization Classifications of Pituitary Neuroendocrine Tumours: A Clinico-Pathological Appraisal. Endocrine-Related Cancer, 30, e230021. [Google Scholar] [CrossRef] [PubMed]
[15] Delellis, R.A., Lloyd, R.V. and Heitz, P.U. (2004) World Health Organization Classification Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs.
[16] Al-Shraim, M. and Asa, S.L. (2005) The 2004 World Health Organization Classification of Pituitary Tumors: What Is New? Acta Neuropathologica, 111, 1-7. [Google Scholar] [CrossRef] [PubMed]
[17] Saeger, W., Lüdecke, D.K., Buchfelder, M., Fahlbusch, R., Quabbe, H. and Petersenn, S. (2007) Pathohistological Classification of Pituitary Tumors: 10 Years of Experience with the German Pituitary Tumor Registry. European Journal of Endocrinology, 156, 203-216. [Google Scholar] [CrossRef] [PubMed]
[18] Kovacs, K., Rotondo, F., Horvath, E., Syro, L.V., Di Ieva, A., Cusimano, M.D., et al. (2014) Letter to the Editor. Endocrine Pathology, 26, 93-94. [Google Scholar] [CrossRef] [PubMed]
[19] Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., et al. (2018) European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas. European Journal of Endocrinology, 178, G1-G24. [Google Scholar] [CrossRef] [PubMed]
[20] Di Ieva, A., Rotondo, F., Syro, L.V., Cusimano, M.D. and Kovacs, K. (2014) Aggressive Pituitary Adenomas—Diagnosis and Emerging Treatments. Nature Reviews Endocrinology, 10, 423-435. [Google Scholar] [CrossRef] [PubMed]
[21] Lloyd, R.V. (2017) WHO Classification of Tumours of Endocrine Organs. 4th Edition, IARC Publications.
[22] Mete, O. and Lopes, M.B. (2017) Overview of the 2017 WHO Classification of Pituitary Tumors. Endocrine Pathology, 28, 228-243. [Google Scholar] [CrossRef] [PubMed]
[23] Lenders, N.F., Earls, P.E., Inder, W.J. and McCormack, A.I. (2023) The Evolution in Pituitary Tumour Classification: A Clinical Perspective. Endocrine Oncology, 3, e220079. [Google Scholar] [CrossRef] [PubMed]

为你推荐